Compare Ryanair Holdings plc (RYAAY) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ryanair Holdings plc vs BIO-TECHNE Corp — how do they compare? Ryanair Holdings plc trades at $58.99 (market cap $29.31B), while BIO-TECHNE Corp trades at $71.63 (market cap $11.16B). The key difference: Ryanair Holdings plc is far larger — about 2.6× BIO-TECHNE Corp's market cap, and Ryanair Holdings plc pays the higher dividend (1.68%). Which is the better fit depends on your goals.
| RYAAY | TECH | |
|---|---|---|
Market Cap | $29.31B | $11.16B |
Sector | Industrials | Health |
52-Week High | $73.82 | $72.12 |
52-Week Low | $53.24 | $43.31 |
Enterprise Value | $26.33B | $11.24B |
Dividend Yield | 1.68% | 0.45% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ryanair Holdings plc
Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.
Read more on RYAAY →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
